SEC Filing Summary: Pieris Pharmaceuticals, Inc. (PIRS)
Business Context and Reporting Period
This Form 8-K was filed on August 4, 2021, by Pieris Pharmaceuticals, Inc., a biopharmaceutical company incorporated in Nevada. The report serves to disclose financial results for the quarter ended June 30, 2021, and includes an investor presentation dated August 2021. The filing references a press release (Exhibit 99.1) and an investor presentation (Exhibit 99.2) as the primary sources for operational details.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and investor presentation (Exhibit 99.2), which are not included in the input text. Consequently, no financial figures can be extracted from this document alone.
Material Changes
The filing announces the release of financial results for the quarter ended June 30, 2021. No specific material changes compared to prior periods are detailed in the text of this 8-K; such comparisons are located in the attached exhibits.
Guidance, Outlook, and Risks
The filing incorporates an August 2021 Investor Presentation (Exhibit 99.2) which likely contains management commentary, outlook, and risk factors. However, the text of the 8-K itself does not summarize specific guidance, risks, contingencies, or unusual items. The document explicitly states that the information in the exhibits is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2021 revenue, net loss, and cash position figures.
- Examine Exhibit 99.2 (Investor Presentation) for updated clinical trial timelines, pipeline progress, and forward-looking guidance.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Confirm any material agreements or regulatory updates mentioned in the attached exhibits.